Company intelligence / Profile preview

Volastra Therapeutics

New York (West Harlem), New York, United Statesvolastratx.com ↗

Ownership: Private
Employees: ~32
Development stage: Phase 1

Overview

Volastra has two KIF18A inhibitors in Phase 1 clinical trials. VLS-1488 is being studied in advanced solid tumors with high levels of chromosomal instability. Sovilnesib (previously AMG650) recently completed a Phase 1 trial and a Phase 1b trial was initiated in early 2024 for platinum-resistant high-grade serous ovarian cancer. Both compounds have received FDA Fast Track designation.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

VLS-1488

4 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers SquibbMicrosoftFunction OncologyTailor BioAmgen

Beyond the preview

Go deeper on Volastra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Volastra Therapeutics.

Explore the full profile